{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-089856","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.764290+00:00","generated_at":"2026-05-15T21:29:48.529871+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint Q4 net loss $67.6M; DURAVYU wet AMD Phase 3 topline due mid-2026","bullets":["Net loss Q4 $67.6M ($0.81/sh) vs $41.4M ($0.64); FY net loss $232M ($3.17) vs $130.9M ($2.32).","Total net revenue Q4 $0.6M vs $11.6M, mainly from YUTIQ deferred revenue recognition.","Cash, cash equivalents & investments $306M as of Dec 31, 2025; provides runway into Q4 2027.","Both Phase 3 wet AMD trials (LUGANO, LUCIA) on track; topline data expected mid-2026. DME trials dosed.","Appointed Michael Campbell as Chief Commercial Officer for DURAVYU launch readiness."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-089856","json":"https://secwatch.observer/filing/0001193125-26-089856.json","markdown":"https://secwatch.observer/filing/0001193125-26-089856.md","text":"https://secwatch.observer/filing/0001193125-26-089856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526089856/0001193125-26-089856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526089856/eypt-20260304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:29:48.529871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}